Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 229Squamous Cell Carcinoma of Head and Neck 138Head and Neck Neoplasms 130Lung Neoplasms 117Esophageal Neoplasms 88Stomach Neoplasms 84Uterine Cervical Neoplasms 66Esophageal Squamous Cell Carcinoma 65Urinary Bladder Neoplasms 59Breast Neoplasms 55Nasopharyngeal Carcinoma 51Small Cell Lung Carcinoma 46Carcinoma, Squamous Cell 39Neoplasm Metastasis 38Pancreatic Neoplasms 36Neoplasms 35Biliary Tract Neoplasms 34Oropharyngeal Neoplasms 32Cholangiocarcinoma 32Ovarian Neoplasms 30Mesothelioma, Malignant 28Adenocarcinoma Of Esophagus 28Lymphoma 25Carcinoma 24Adenocarcinoma of Lung 24Central Nervous System Neoplasms 22Laryngeal Neoplasms 20Carcinoma, Ovarian Epithelial 20Recurrence 19Lymphoma, Large B-Cell, Diffuse 19

Interventions

pembrolizumab 1Taxes 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Staging IV NSCLC × Cisplatin × Clear all
NCT04094909 2020-02-07

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Guangzhou Institute of Respiratory Disease

Phase 2 Unknown
186 enrolled
Thoracic

Staging IV NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡